Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1341 Views
Dr Anil Bhansali, Chandigarh 19 November 2018
Evolution of immune check point inhibitors (ICPi) is a breakthrough in the management of metastatic carcinomas. ICPi include CTLA-4 inhibitor ipilimumab; PD-1 inhibitors and PDL-1 inhibitors. Recognition of endocrine complications following ICPi therapy requires a high index of suspicion. Thyroid dysfunction and hypophysitis are common endocrine consequences. Development of endocrine complications predicts favorable outcome. Those with pre-existing hypothyroidism may require increase in dose after initiation of ICPi therapy. Discontinuation of ICPi is not warranted unless patient is severely thyrotoxic.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}